NASDAQ: TELOTelomir Pharmaceuticals Inc Stock
$1.25-0.03 (-2.34%)
Updated Jun 17, 2026
TELO Price
$1.25
Fair Value Price
$0.23
Market Cap
$85.97M
52 Week Low
$1.05
52 Week High
$3.10
P/E
-4.31x
P/B
17.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.22M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$5M
Beta
1.24
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TELO Overview
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TELO's potential to beat the market
- TELO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TELO
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.93 | A | |
| $52.44 | A | |
| $16.14 | A |
Be the first to know about important TELO news, forecast changes, insider trades & much more!
TELO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TELO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TELO ($1.25) is overvalued by 443% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TELO ($1.25) is not significantly undervalued (443%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TELO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TELO due diligence checks available for Premium users.
Valuation
TELO fair value
Fair Value of TELO stock based on Discounted Cash Flow (DCF)
Price
$1.25
Fair Value
$0.23
Overvalued by
443.00%
TELO ($1.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TELO ($1.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TELO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TELO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.31x
Industry
14.91x
Market
12.4x
TELO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.32x
Industry
4.94x
TELO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TELO's financial health
Profit margin
Revenue
$0.0
Net Income
-$990.9k
Profit Margin
0%
TELO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.8M
Liabilities
$827.3k
Debt to equity
0.17
TELO's short-term assets ($5.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TELO's short-term assets ($5.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TELO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$47.4k
TELO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TELO vs Biotech Stocks
Telomir Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.